Shares of Proteostasis Therapeutics Inc. (PTI) slightly recovered during today’s trading after huge drop on Monday’s session when company announced results from a phase 1 study of its cystic fibrosis (CF) treatment.
BOSTON, March 25, 2019 /PRNewswire/ — Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced results from Phase 1 clinical studies of its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators: PTI-801, a third-generation CFTR corrector; PTI-808, a novel CFTR potentiator; and PTI-428, a novel CFTR amplifier. This comprehensive data set includes efficacy and safety data from 14-day studies of PTI’s proprietary combination therapy (PTI-808, PTI-801 and PTI-428), as well as separate studies of PTI-801 over 14 days and PTI-428 over 28 days as add-on treatments to background tezacaftor/ivacaftor therapy, in CF subjects. Endpoints including safety, changes in sweat chloride (SC) concentration and in percent predicted FEV1 (ppFEV1) were assessed and evaluated.
That was definitely market overreaction hence some recovery is expecting in upcoming days.
On 25 March, Equities researchers from Cantor Fitzgerald sent note to clients and investors of Proteostasis Therapeutics Inc (PTI) where they initiated a “buy” rating with target of $14/share.
Cantor Fitzgerald has offices and trading desks in all major financial centers throughout the world. Company specialize in the following areas:
Equities: Cantor Fitzgerald is one of the largest and best known participants in the global equity capital arena.
Fixed Income & Currencies: from its roots in bond brokerage, Cantor has risen to become a world-renowned dealer in fixed income products.
Investment Banking: Cantor Fitzgerald’s Investment Banking division offers capital raising and advisory services to both growth-oriented and mature companies.
Prime Services: Cantor Prime Services (CPS) is a global, multi-asset prime brokerage platform with a focus on the quality middle market.
Real Estate: discover exceptional opportunities with Cantor’s growing Real Estate platform.
Affiliates: Cantor Fitzgerald’s affiliate businesses include: BGC Partners, Inc. (BGC), Newmark Knight Frank (NKF), and GFI Group (GFI).
Analysts from H.C. Wainwright reiterated Buy Rating for Proteostasis Therapeutics Inc (PTI) as of March 26th with target price of $15/share.
H.C. Wainwright & Co. was founded in 1868 at the Union Bank Building in Boston, Massachusetts, located at the heart of the strongest financial center in post-Civil War America. Housed at 40 State Street in the same building as the Boston Stock Exchange, H.C. Wainwright & Co. had the advantage of crafting each line of business in-step with the financial landscape of the time. Furthermore, the firm’s location on State Street, where the activities of a thriving merchant port converged with the commerce of downtown Boston, provided a cutting-edge environment for experience and growth. Quickly becoming a prominent and respected member of the Exchange, H.C. Wainwright & Co.’s values of discipline, trust, and client stewardship set the company on a distinctly reputable trajectory towards financial stability and dependability.